Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Telomir Pharmaceuticals (TELO) selected Linical to support its FDA-cleared Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer. Telomir signed a master services agreement and a clinical trial work order with Linical and is targeting a trial start in the first quarter of 2027.
The trial will test Telomir-Zn on its own in patients with advanced or metastatic disease. It will assess safety, how well patients tolerate the drug, how the drug moves through and affects the body, and early signs of activity against tumors.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointSigned agreements with Linical establish the framework for preparing the Telomir-Zn trial.
- Moderate pointFDA clearance of Telomir-Zn’s Investigational New Drug application allows the Phase 1/2 trial to proceed.
- Minor point. Forward-looking: it has not happened yet and may not happen.Phase 1/2 trial start is targeted for the first quarter of 2027.
Negative
- None.
Key Figures
- Trial phase
- Phase 1/2
- FDA-cleared study in advanced or metastatic TNBC
- Targeted clinical initiation
- First quarter of 2027
- Timing targeted for the study
Previous Clinical trial Reports
-
GLP toxicology reported no treatment-related adverse or dose-limiting toxicities before planned first-in-human studies.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cro technical
pharmacokinetics medical
pharmacodynamics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Global CRO Brings Extensive Oncology Experience, Including Breast Cancer and Early-Phase Clinical Development
Executed Clinical Trial Agreements Support Targeted Clinical Initiation in the First Quarter of 2027
MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (“Telomir” or the “Company”), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, today announced that it has selected Linical, a global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC).
Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, targeted for the first quarter of 2027.
The engagement follows the U.S. Food and Drug Administration's clearance of Telomir's Investigational New Drug (IND) application and represents an important operational milestone as the Company advances toward clinical execution.
“Following FDA clearance of our IND, our priority has been to establish the clinical infrastructure necessary to advance Telomir-Zn into patients,” said Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals. “We selected Linical for its extensive oncology experience, including breast cancer and early-phase clinical development. With our clinical trial agreements now executed, we are focused on advancing toward clinical initiation in the first quarter of 2027 and evaluating the potential of our novel oral epigenetic therapy in patients with triple-negative breast cancer.”
“We are pleased to partner with Telomir Pharmaceuticals as it prepares to evaluate Telomir-Zn in patients with triple-negative breast cancer,” said Clareece West, President at Linical. “Our CRO team brings extensive experience in oncology and early-phase clinical development to this partnership, and we look forward to helping Telomir advance their important clinical program.”
Linical's Oncology and Breast Cancer Expertise
Linical is a global CRO with more than two decades of experience supporting oncology clinical development, including breast cancer and other solid tumors. Linical has completed numerous oncology clinical trials, with approximately half of its oncology experience concentrated in early-phase studies.
Linical’s oncology capabilities span Phase 1 through Phase 4 clinical development, encompassing clinical trial startup, investigator-site coordination, patient recruitment, clinical monitoring, project management, biometrics, and regulatory support.
Linical's established oncology infrastructure and experience in breast cancer research align with the operational needs of Telomir's planned clinical program, supporting the company's preparations for clinical evaluation of Telomir-Zn.
Advancing a Novel Oral Epigenetic Therapy for Triple-Negative Breast Cancer
Telomir-Zn is an investigational oral epigenetic therapy designed to regulate intracellular metal homeostasis and potentially reactivate silenced tumor suppressor genes involved in controlling cancer growth.
The therapeutic approach is based on the role of intracellular metals, particularly iron, in regulating epigenetic processes. Certain cancers, including triple-negative breast cancer, exhibit increased dependence on iron-related biological pathways which support their uncontrolled growth. By modulating intracellular metal availability, Telomir-Zn inhibits several key iron-dependent epigenetic enzymes, thereby potentially restoring tumor suppressor gene functions.
Preclinical research has demonstrated antitumor activity in TNBC models, supporting further investigation of Telomir-Zn in cancers with elevated iron dependency.
In this upcoming FDA-cleared Phase 1/2 clinical study, Telomir will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of Telomir-Zn as a monotherapy in patients with advanced or metastatic TNBC.
The Company is advancing clinical trial preparations with Linical and continues to target clinical initiation in the first quarter of 2027.
About Linical
Linical is a global contract research organization providing comprehensive clinical development services to pharmaceutical and biotechnology companies. With operations across North America, Europe, and Asia-Pacific, Linical supports clinical trials across multiple therapeutic areas (including oncology, neurology, immunology, endocrinology, and rare disease) with a significant focus on early-phase clinical development.
For more information, visit www.linical.com.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.
For more information, please visit https://telomirpharma.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words.
Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the anticipated closing of the financing described herein, the expected proceeds from and intended use of such proceeds, the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.
These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.
Contact Information
Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.